VANECK VECTORS ETF TR's ticker is GDX and the CUSIP is 92189F106. A total of 740 filers reported holding VANECK VECTORS ETF TR in Q1 2023. The put-call ratio across all filers is 0.38 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $757,511 | +27.5% | 22,326 | +18.8% | 0.03% | +145.5% |
| Q1 2024 | $594,146 | -1.3% | 18,790 | -13.6% | 0.01% | -45.0% |
| Q4 2023 | $602,246 | -54.1% | 21,750 | -55.4% | 0.02% | -60.0% |
| Q3 2023 | $1,312,555 | +46.5% | 48,776 | +63.9% | 0.05% | +51.5% |
| Q2 2023 | $895,975 | +32.5% | 29,757 | +42.3% | 0.03% | +26.9% |
| Q1 2023 | $676,398 | +121335.9% | 20,909 | +7.6% | 0.03% | -16.1% |
| Q4 2022 | $557 | -99.7% | 19,439 | +151.5% | 0.03% | +181.8% |
| Q3 2022 | $186,000 | -40.4% | 7,728 | -32.3% | 0.01% | -15.4% |
| Q2 2022 | $312,000 | -70.3% | 11,407 | -58.4% | 0.01% | -53.6% |
| Q1 2022 | $1,051,000 | +189.5% | 27,417 | +141.6% | 0.03% | +250.0% |
| Q4 2021 | $363,000 | +16.3% | 11,347 | +7.3% | 0.01% | 0.0% |
| Q3 2021 | $312,000 | -42.2% | 10,575 | -33.5% | 0.01% | -46.7% |
| Q2 2021 | $540,000 | -19.3% | 15,897 | -24.5% | 0.02% | -16.7% |
| Q1 2021 | $669,000 | – | 21,066 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 738,500 | $19,873,035 | 80.92% |
| New Harbor Financial Group, LLC | 1,680,752 | $45,229,033 | 14.96% |
| TORQ CAPITAL MANAGEMENT (HK) Ltd | 139,000 | $3,740,490 | 9.95% |
| Vanderbilt University | 1,360,540 | $36,612,131 | 9.45% |
| Eschler Asset Management LLP | 300,000 | $8,073,000 | 9.42% |
| New Harbor Financial Group, LLC | 1,027,300 | $27,644,643 | 9.15% |
| Guild Investment Management, Inc. | 139,333 | $3,749,454 | 6.28% |
| Monaco Asset Management SAM | 750,000 | $20,182,500 | 5.98% |
| STRATEGIC INVESTMENT MANAGEMENT, LLC | 132,460 | $3,867,832 | 4.74% |
| PCG Wealth Advisors, LLC | 264,614 | $7,120,782 | 4.67% |